Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, and effectiveness of a drug called QD202 in adults with acute ischemic stroke who are receiving thrombolysis but not endovascular thrombectomy. This randomized, double-blinded, placebo-controlled phase II trial aims to better understand how QD202 works and is tolerated in this patient group. The study is sponsored by Shanghai QuietD Biotechnology Co., Ltd. and will include up to 120 male and female participants aged 18 to 85 years. Participants will be randomly assigned to one of three groups two experimental groups receiving different doses of QD202 100 mg on Day 1 followed by either 5 mg or 10 mg daily from Day 2 to Day 5 or a placebo group receiving a matching placebo daily for five days. The study drug or placebo is given as a 60-minute intravenous infusion after completion of thrombolysis. The trial includes a treatment period of five days and follow-up visits on Day 7 or discharge day, Day 30, and Day 90. During the study, participants will undergo assessments including stroke severity scales such as the National Institutes of Health Stroke Scale NIHSS, functional outcome measures like the modified Rankin Scale mRS and Barthel Index BI, and blood tests to monitor drug levels and safety. Safety and tolerance will be followed through Day 90. Participants will have multiple visits during this period for evaluations of their neurological status and overall health.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Yangxinshi tablets in patients with coronary heart disease combined with cardiac dysfunction. This study aims to determine if adding Yangxinshi tablets to standard treatment can reduce heart-related events, enhance exercise capacity, and improve quality of life and mental health. The trial includes 2708 patients and is a Phase 4 randomized controlled study sponsored by SPH Qingdao Growful Pharmaceutical Co., Ltd. Participants are randomly assigned to one of two groups one group receives conventional treatment plus Yangxinshi tablets 3 tablets taken orally three times a day, while the control group receives conventional treatment alone. Conventional treatment includes drugs such as aspirin, beta-blockers, statins, and others for symptom relief and improving heart outcomes. The treatment continues until a set number of heart-related events occur or the study ends. Throughout the study, participants undergo regular assessments including measurements of heart events, exercise tolerance, heart function tests, blood markers, and mental health questionnaires over an average of three years. Additional evaluations at 24 and 48 weeks include depression and anxiety scales, echocardiography, and exercise testing. The research team closely monitors safety, quality of life, and heart function throughout the study period.
Actively Recruiting
Researchers are evaluating early minimally invasive surgery with thrombolysis eMIST compared to the best medical management in patients with acute spontaneous supratentorial intracerebral hemorrhage ICH of 20 mL or more. This multicenter, randomized, adaptive clinical trial aims to improve functional outcomes after stroke caused by this type of brain hemorrhage. The trial uses a prospective, open-label design with blinded assessment of results and includes adaptive sample size estimation based on interim follow-up data. Participants are randomly assigned to receive either early minimally invasive catheter evacuation followed by up to ten doses of urokinase to dissolve the clot, or the best available standard medical care without surgery. The urokinase doses are administered through a catheter placed directly into the hemorrhage site, aiming for clot resolution. The randomized intervention must start within specific timing windows after stroke onset to be included. During the study, participants undergo assessments including head CT scans, functional evaluations using the utility-weighted modified Rankin Scale at multiple time points up to 180 days, and other measures such as quality of life and daily living activities. Safety and efficacy are monitored throughout the trial, which lasts until study completion in 2028. Researchers focus on functional improvement as the primary outcome, with additional secondary measurements including mortality and clot removal at defined times.